Bladder cancer (BC) is the tenth most common cancer worldwide, and its associated five-year survival rate declines rapidly (from 96% to 6%) as it progresses from in situ through local invasion, regional spread and finally to distal spread. Thus, early detection and timely therapeutic interventions are crucial to improve outcomes and reduce the burden of disease. Outcomes have been further improved by the integration of recently approved therapies for BC, the utilization of biomarkers to guide treatment plans and the opportunity for eligible patients with BC to enroll in clinical trials. For all treatment plans, effective communication among the health care team is crucial for providing comprehensive care for this condition. This activity will provide participants with an overview of early BC diagnosis and its impact on survival rates. It will explore recently approved therapies for BC both as standalone treatments and in combination with established therapeutic approaches. Emerging therapies and their potential benefits will be examined, and the value of biomarkers will be discussed. Participants will gain insight into treatment strategies to optimize patient outcomes in BC.

This activity will provide an overview of cardiovascular risk factors specific to women and explore the latest strategies and tools for assessing and mitigating these risks and improving overall cardiovascular care.

Essentials of Oncology and Transplant Management is designed for all who are interested in learning best practices for optimal patient and/or benefit management in the fields of transplant medicine and oncology.

Essentials of Oncology and Transplant Management is designed for all who are interested in learning best practices for optimal patient and/or benefit management in the fields of transplant medicine and oncology.